Bernhard G Weiss1, Mahalia Zoe Anczykowski2, Stefan Küffer3, Jennifer L Spiegel4, Mattis Bertlich4, Martin Canis4, Friedrich Ihler4,5, Julia Kitz3, Mark Jakob4. 1. Department of Otorhinolaryngology, LMU University Hospital, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, Munich, Germany. Bernhard.Weiss@med.uni-muenchen.de. 2. Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. 3. Institute of Pathology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. 4. Department of Otorhinolaryngology, LMU University Hospital, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, Munich, Germany. 5. German Center for Vertigo and Balance Disorders (DSGZ), LMU University Hospital, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, Munich, Federal Republic of Germany.
Abstract
PURPOSE: p16 overexpression was considered as surrogate marker to identify human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCCs). METHODS: 102 patients with advanced stage OPSCCs treated primarily by transoral lasermicrosurgery were included. Prognostic associations of p16- and HPV-status were analyzed separately and combined. RESULTS: In contrast to p16, the HPV-status resulted in no significant survival discrepancies (5-year overall survival (OS) HPV-positive 64.9%, HPV-negative 78.7%). Combining both markers, p16-positive (p16-positive/HPV-positive, p16-positive/HPV-negative) and p16-negative/HPV-negative groups demonstrated comparable high survival (OS 78.1% vs. 85.6% vs. 73.6%). Lowest survival was observed for patients with p16-negative/HPV-positive OPSCCs (OS 40.8%). Never smoking patients with p16-positive OPSCCs demonstrated the highest survival, whereas within former/current smokers with p16-positive and p16-negative disease it was comparable low (OS 90.0% vs. 63.0% vs. 57.4%). CONCLUSIONS: p16- and HPV-status should not be considered as equivalent markers for a better prognosis. Furthermore, they should not generally predominate patient associated factors like smoking.
PURPOSE:p16 overexpression was considered as surrogate marker to identify human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCCs). METHODS: 102 patients with advanced stage OPSCCs treated primarily by transoral lasermicrosurgery were included. Prognostic associations of p16- and HPV-status were analyzed separately and combined. RESULTS: In contrast to p16, the HPV-status resulted in no significant survival discrepancies (5-year overall survival (OS) HPV-positive 64.9%, HPV-negative 78.7%). Combining both markers, p16-positive (p16-positive/HPV-positive, p16-positive/HPV-negative) and p16-negative/HPV-negative groups demonstrated comparable high survival (OS 78.1% vs. 85.6% vs. 73.6%). Lowest survival was observed for patients with p16-negative/HPV-positive OPSCCs (OS 40.8%). Never smoking patients with p16-positive OPSCCs demonstrated the highest survival, whereas within former/current smokers with p16-positive and p16-negative disease it was comparable low (OS 90.0% vs. 63.0% vs. 57.4%). CONCLUSIONS:p16- and HPV-status should not be considered as equivalent markers for a better prognosis. Furthermore, they should not generally predominate patient associated factors like smoking.
Entities:
Keywords:
Head and neck squamous cell carcinomas (HNSCC); Human papillomavirus (HPV); Oropharyngeal cancer; Oropharyngeal squamous cell carcinoma; Prognosis; p16
Authors: Hisham Mehanna; Tom Beech; Tom Nicholson; Iman El-Hariry; Christopher McConkey; Vinidh Paleri; Sally Roberts Journal: Head Neck Date: 2012-01-20 Impact factor: 3.147
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Jay S Cooper; Kim Porter; Katherine Mallin; Henry T Hoffman; Randal S Weber; Kian K Ang; E Greer Gay; Corey J Langer Journal: Head Neck Date: 2009-06 Impact factor: 3.147
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Anil K Chaturvedi; William F Anderson; Joannie Lortet-Tieulent; Maria Paula Curado; Jacques Ferlay; Silvia Franceschi; Philip S Rosenberg; Freddie Bray; Maura L Gillison Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Mia Hashibe; Paul Brennan; Shu-Chun Chuang; Stefania Boccia; Xavier Castellsague; Chu Chen; Maria Paula Curado; Luigino Dal Maso; Alexander W Daudt; Eleonora Fabianova; Leticia Fernandez; Victor Wünsch-Filho; Silvia Franceschi; Richard B Hayes; Rolando Herrero; Karl Kelsey; Sergio Koifman; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Juan J Lence; Dana Mates; Elena Matos; Ana Menezes; Michael D McClean; Joshua Muscat; Jose Eluf-Neto; Andrew F Olshan; Mark Purdue; Peter Rudnai; Stephen M Schwartz; Elaine Smith; Erich M Sturgis; Neonilia Szeszenia-Dabrowska; Renato Talamini; Qingyi Wei; Deborah M Winn; Oxana Shangina; Agnieszka Pilarska; Zuo-Feng Zhang; Gilles Ferro; Julien Berthiller; Paolo Boffetta Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-02-03 Impact factor: 4.254
Authors: Devasena Anantharaman; Behnoush Abedi-Ardekani; Daniel C Beachler; Tarik Gheit; Andrew F Olshan; Kathy Wisniewski; Victor Wunsch-Filho; Tatiana N Toporcov; Eloiza H Tajara; José Eduardo Levi; Raquel A Moyses; Stefania Boccia; Gabriella Cadoni; Guido Rindi; Wolfgang Ahrens; Franco Merletti; David I Conway; Sylvia Wright; Christine Carreira; Helene Renard; Priscilia Chopard; Sandrine McKay-Chopin; Ghislaine Scelo; Massimo Tommasino; Paul Brennan; Gypsyamber D'Souza Journal: Int J Cancer Date: 2017-02-14 Impact factor: 7.396